MorphoSys shares jump amid Tremfya guidance, MOR208 data

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) shares rose Nov. 6 after the company said in its 3Q18 earnings that plaque psoriasis drug Tremfya guselkumab could generate 2018 royalties at the upper end of the biotech's previous guidance. MorphoSys also reported EPS that was well ahead of the consensus estimates after the company pared back R&D spending by nearly half over the prior-year quarter.

MorphoSys gained $4.17 (17%) to $28.95 on NASDAQ and €7.55 to €102.50 in Germany...